Pulmonary arterial hypertension

Rationale 1

Pulmonary Arterial Hypertension & Systemic sclerosis with ongoing digital ulcer disease 

Brand: Tracleer

Rationale 1

Review Date: 01/12/2022

Pulmonary Hypertension (primary)

Brand: Eudemine

Rationale: 1,2

Primary pulmonary hypertension

Rationale 1

Ischaemia (severe chronic) of lower limbs in patients at risk of amputation, in whom surgical revascularisation or angioplasty has failed or is not indicated

Raynaud's phenomena (severe)in patients with progressive trophic disorder

Rationale 1

Pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III.

Rationale 1,6

Pulmonary Hypertension - Improvement of exercise capacity in adults with WHO Functional Class (FC) II-III chronic thromboembolic pulmonary hypertension that is inoperable or persistent or recurrent after surgical treatment, or WHO FC II-III pulmonary arterial hypertension. 

Rationale 1,6

Pulmonary Hypertension, WHO functional class II & III

Patients treated for Pulmonary Arterial Hypertension, NHSE commissioned.

For Erectile Dysfunction see sildenafil entries in section 7.4.5

Rationale 1,6

NICE Guidance 

NHS England commissioning policy

Patients treated for Pulmonary Arterial Hypertension, NHSE commissioned.

For Erectile Dysfunction see Tadalafil entries in section 7.4.5

Brand : Adcirca

Rationale 1,6

NHS England commissioning policy

Idiopathic or heritable pulmonary arterial hypertension

Rationale 1,6

NHS England commissioned - Specialist Centre Only

Use in combination with other pulmonary arterial hypertension (PAH) therapies, for the treatment of PAH in adults with WHO Functional Class II to III, to improve exercise capacity

NICE TA in development